
- /
- Supported exchanges
- / US
- / CRTHF.PINK
CARsgen Therapeutics Holdings Limited (CRTHF PINK) stock market data APIs
CARsgen Therapeutics Holdings Limited Financial Data Overview
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of R/R MM, relapsed/refractory primary plasma cell leukemia (R/R pPCL), relapsed/refractory plasma cell leukemia (R/R PCL), and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT059X, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R/ MM and R/R PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2114 that are in the pre-clinical stage for the treatment of solid tumors; and KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence. The company was founded in 2014 and is headquartered in Shanghai, China.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get CARsgen Therapeutics Holdings Limited data using free add-ons & libraries
Get CARsgen Therapeutics Holdings Limited Fundamental Data
CARsgen Therapeutics Holdings Limited Fundamental data includes:
- Net Revenue: 39 425 K
- EBITDA: -686 611 968
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get CARsgen Therapeutics Holdings Limited End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CARsgen Therapeutics Holdings Limited News

Would Shareholders Who Purchased Crest Nicholson Holdings' (LON:CRST) Stock Five Years Be Happy With The Share price Today?
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For example the Crest Nicholson Holdings plc (LON:CRST) share price dropped 68% over ...


Would Shareholders Who Purchased Crest Nicholson Holdings' (LON:CRST) Stock Five Years Be Happy With The Share price Today?
We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For example the Crest Nicholson Holdings plc (LON:CRST) share price dropped 68% over ...

Should You Be Impressed By Crest Nicholson Holdings' (LON:CRST) Returns on Capital?
If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conj...

Should You Be Impressed By Crest Nicholson Holdings' (LON:CRST) Returns on Capital?
If you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conj...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.